trending Market Intelligence /marketintelligence/en/news-insights/trending/u0amb1qvzhajxbk6-4ls2g2 content esgSubNav
In This List

Mirati Therapeutics closes common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Mirati Therapeutics closes common stock offering

Mirati Therapeutics Inc. closed an underwritten public offering of 3,162,500 common shares priced $38.85 each.

The San Diego-based cancer drug developer raised about $139.2 million through the offering.

Underwriters exercised their option to buy 412,500 common shares. Certain investor bought pre-funded warrants to buy 421,650 common shares, in lieu of stock.

Cowen, Barclays and SunTrust Robinson Humphrey acted as joint book-running managers for the offering, with Oppenheimer & Co. as lead manager and H.C. Wainwright & Co. as co-manager.